Clinical Trial Update: Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of panobinostat in relapsed or refractory non-Hodgkin lymphoma completed; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Panobinostat (Panobinostat)

Snippet

Sponsor: Mayo Clinic | Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2018-05-17